Ronny Drapkin

Active 1993–2025

141
Papers
28,218
Citations
83
h-index
133
i10-index

Citations

Citations per year for Ronny Drapkin1987: 1 citations1993: 3 citations1994: 33 citations1995: 65 citations1996: 98 citations1997: 116 citations1998: 86 citations1999: 51 citations2000: 46 citations2001: 52 citations2002: 66 citations2003: 65 citations2004: 92 citations2005: 119 citations2006: 124 citations2007: 153 citations2008: 177 citations2009: 161 citations2010: 197 citations2011: 256 citations2012: 261 citations2013: 309 citations2014: 257 citations2015: 342 citations2016: 361 citations2017: 375 citations2018: 342 citations2019: 964 citations2020: 1,085 citations2021: 1,014 citations2022: 837 citations2023: 645 citations2024: 981 citations2025: 548 citations2026: 13 citations1988–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,927 citing papers, 32.1% of this breakdownChina: 1,506 citing papers, 12.3% of this breakdownUnited Kingdom: 887 citing papers, 7.3% of this breakdownCanada: 583 citing papers, 4.8% of this breakdownGermany: 509 citing papers, 4.2% of this breakdownItaly: 397 citing papers, 3.2% of this breakdownFrance: 379 citing papers, 3.1% of this breakdownAustralia: 370 citing papers, 3% of this breakdownJapan: 354 citing papers, 2.9% of this breakdownNetherlands: 326 citing papers, 2.7% of this breakdownSpain: 232 citing papers, 1.9% of this breakdownSwitzerland: 212 citing papers, 1.7% of this breakdown
0%32.1%Other 20.8%

Fields

  • Biochemistry, Genetics and Molecular Biology53.4%
  • Medicine38.7%
  • Immunology and Microbiology3.2%
  • Agricultural and Biological Sciences1.2%
  • Neuroscience0.9%
  • Engineering0.8%
  • Other1.8%

Topics

  • Ovarian cancer diagnosis and treatment6.1%
  • DNA Repair Mechanisms5.6%
  • PARP inhibition in cancer therapy3.7%
  • CRISPR and Genetic Engineering2.8%
  • RNA modifications and cancer2.7%
  • Cancer-related molecular mechanisms research2.4%
  • Other76.7%

Coauthors

All papers

Open in search
  1. Nociceptor neurons affect cancer immunosurveillance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nader Ghasemlou, Paola D. Vermeer, Clifford J. Woolf, Sébastien Talbot - Nature 2022 cited by 325

  2. Whole–genome characterization of chemoresistant ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia O’Brien, Jodie Leditschke, Greg Young, Kate Strachan, Paul Waring, Walid J. Azar, Thomas J. Mitchell, Nadia Traficante, Joy Hendley, Heather Thorne, Mark Shackleton, David K. Miller, Gisela Mir Arnau, Richard W. Tothill, Timothy P. Holloway, Timothy Semple, Ivon Harliwong, Craig Nourse, Ehsan Nourbakhsh, Suzanne Manning, Senel Idrisoglu, Timothy J. C. Bruxner, Angelika N. Christ, Barsha Poudel, Oliver Holmes, Matthew J. Anderson, Conrad Leonard, Andrew Lonie, Nathan E. Hall, Scott Wood, Darrin F. Taylor, Qinying Xu, J. Lynn Fink, Nick M. Waddell, Ronny Drapkin, Euan A. Stronach, Hani Gabra, Robert Brown, Andrea Jewell, Shivashankar H. Nagaraj, Emma Markham, Peter J. Wilson, Jason Ellul, Orla McNally, Maria Doyle, Ravikiran Vedururu, Collin Stewart, Ernst Lengyel, John V. Pearson, Nicola Waddell, Anna DeFazio, Sean M. Grimmond, David D.L. Bowtell - Nature 2015 cited by 1,658

  3. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven A. Narod, Brad H. Nelson, Kenneth P. Nephew, Paul D.P. Pharoah, Daniel J. Powell, Pilar Ramos, Iris L. Romero, Clare L. Scott, Anil K. Sood, Euan A. Stronach, Frances R. Balkwill - Nature reviews. Cancer 2015 cited by 1,425

  4. High grade serous ovarian carcinomas originate in the fallopian tube

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2017 cited by 767

  5. Tumor innervation: peripheral nerves take control of the tumor microenvironment

    Authors: , - Journal of Clinical Investigation 2021 cited by 204

  6. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Structural & Molecular Biology 2010 cited by 1,021

  7. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2021 cited by 125

  8. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 86

  9. Rethinking ovarian cancer: recommendations for improving outcomes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature reviews. Cancer 2011 cited by 1,507

  10. C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 cited by 77

  11. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , - Cancer Research 2021 cited by 176

  12. Functional neuronal circuits promote disease progression in cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Science Advances 2023 cited by 89

  13. Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

    Authors: , , , , , , , , , , , , , , , - Cancer Cell 2013 cited by 607

  14. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , - Science 2011 cited by 595

  15. Tumor Innervation: Cancer Has Some Nerve

    Authors: , , - Trends in cancer 2020 cited by 120

  16. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Soslow, Anna DeFazio, Michael J. Birrer, Joe W. Gray, John N. Weinstein, David D.L. Bowtell, Ronny Drapkin, Jill P. Mesirov, Gad Getz, Douglas A. Levine, Matthew Meyerson - Journal of Clinical Investigation 2012 cited by 591

  17. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Gynecologic Oncology 2021 cited by 117

  18. Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael S. Anglesio, David G. Huntsman, Simon A. Gayther, Jason Konner, Francesmary Modugno, Kate Lawrenson, Ellen L. Goode, Elli Papaemmanuil - Clinical Cancer Research 2022 cited by 103

  19. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennifer E. Fairman, Euihye Jung, Kshitij S. Arora, Osman H. Yilmaz, Sonia Cohen, Tatyana Sharova, Gary Chi, Bryanna L. Norden, Yuhui Song, Linda T. Nieman, Leontios Pappas, Aparna R. Parikh, Matthew R. Strickland, Ryan B. Corcoran, Tomas Mustelin, George Eng, Ömer H. Yilmaz, Ursula A. Matulonis, Andrew T. Chan, Steven J. Skates, Bo R. Rueda, Ronny Drapkin, Samuel J. Klempner, Vikram Deshpande, David T. Ting, Michael P. Rout, John LaCava, David R. Walt, Kathleen H. Burns - Cancer Discovery 2023 cited by 85

  20. The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity

    Authors: , , , , , , , , , , - Cancer Immunology Research 2021 cited by 71

  21. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

    Authors: , , , , , , , , , , , , , , - Cell 2015 cited by 377

  22. A candidate precursor to serous carcinoma that originates in the distal fallopian tube

    Authors: , , , , , , , , , , , , - The Journal of Pathology 2006 cited by 909

  23. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth

    Authors: , , , , , , , , , , , , , , , , , , , - Molecular Cell 2015 cited by 272

  24. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

    Authors: , , , , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 147